PWM
GILD icon

Parkworth Wealth Management’s Gilead Sciences GILD Stock Holding History

Parkworth Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$3.44K Buy
31
+13
+72% +$1.38K ﹤0.01% 206
2025
Q1 		$2.02K Buy
18
+2
+13% +$206 ﹤0.01% 179
2024
Q4 		$1.48K Buy
+16
New +$1.44K ﹤0.01% 220

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parkworth Wealth Management's GILD Position: Q2 2025 in Review

Parkworth Wealth Management increased its Gilead Sciences (GILD) stake by 72% in Q2 2025, buying an estimated $1.38K and bringing the position to 31 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #206.

Parkworth Wealth Management first reported a position in GILD in Q4 2024 and has held it in 3 quarters since. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Parkworth Wealth Management held 31 shares of Gilead Sciences worth $3.44K as of Q2 2025.
  • Parkworth Wealth Management bought 13 Gilead Sciences shares in Q2 2025, an estimated $1.38K.
  • Gilead Sciences made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #206 holding.
  • Parkworth Wealth Management first reported a position in Gilead Sciences in Q4 2024 and has held it in 3 quarters since.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.